Orthopedic Trauma Devices Market Expected to Account for US$ 14 Bn by 2028

Posted On May 8, 2018 By OrthoSpineNews In Extremities, Top Stories /

VALLEY COTTAGE, New York, May 8, 2018 /PRNewswire/ —

Primarily driven by increasing instances of fractures due to road accidents and sports related injuries, the global market for orthopedic trauma devices is anticipated to expand at a promising CAGR of 6.8% over the next decade. By the end of 2028, the orthopedic trauma devices market is estimated to attain the global revenues beyond US$ 14 Bn. As per the research presented in a recently published report by Future Market Insights, titled “Orthopedic Trauma Devices Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment, 2018 – 2028,” the market will also continue to be driven by impactful presence of some of the local players within respective regional markets.

“While the advent of 3D printing technology is likely to present the market a heap of new growth opportunities in 3D printed orthopedic implants, another significant opportunities lies in the popularly trending reverse shoulder arthroplasty. The rise of digital orthopedics will continue to fuel market growth through to 2028,” states a research analyst at Future Market Insights.

(Logo: https://mma.prnewswire.com/media/677274/Future_Market_Insights_Logo.jpg )

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-2840

Based on the regional analysis, the global orthopedic trauma devices market will continue to witness dominance of North America, which currently accounts for a major portion of the total revenues. With around 48% value share observed in 2017, North America’s orthopedic trauma devices market is estimated to attain a value in excess of US$ 6 Bnby the end of 2028. Western Europe is also identified to be a key market, holding the second largest position in terms of value. Manufacturers will however discover attractive opportunities in developing economies, including Asia Pacific, Latin America, and Middle East and Africa. Among the emerging regional markets, Asia Pacific excluding China and Japan (APECJ) is likely to emerge at a relatively higher pace, followed by MEA. China is expected to be the most lucrative market owing to the highest estimated CAGR value over 2018-2028. Strong presence of key companies will reportedly uplift the markets in North America and China.

Preview Orthopedic Trauma Devices Market Segmentation by Product Type – Internal Fixators, Screws, Plates, Intramedullary Nails, Others, External Fixators, Unilateral Fixators, Circular Fixators, Hybrid Fixators; by end user – Hospitals, Orthopedic and Trauma Centers, Ambulatory Surgical Centers: https://www.futuremarketinsights.com/reports/orthopedic-trauma-devices-market

A majority of the key companies operating in the global orthopedic trauma market are opting for strategic mergers and acquisitions, in addition to new product launches. According to the report, most of the revenue is contributed by the tier 1 companies, followed by the tier 3 players. The tier 1 includes DePuy Synthes Inc., Stryker Corporation, Zimmer Biomet Holdings Inc., and Smith & Nephew Plc., which collectively represent nearly 70% share of the total market revenues. Among these, DePuy and Stryker will continue to remain the top players worldwide over the next decade. Tier 3 accounts for a relatively decent revenue share and includes brands such as Arthrex, Inc., RTISurgical, Medartis, Integra LifeSciences Corporation, Japan MDM, S. H. Pitkar Orthotools Pvt Ltd, Weigao Group Co Ltd, and Invibio Ltd.

Others operating in the global orthopedic trauma devices market include Johnson & Johnson Services, Inc., Wright Medical Group NV, B. Braun Melsungen AG, Orthofix International, and OsteoMed. Growing outpatient surgical procedure demand and boosting funds for delivery of the top-notch trauma care are foreseen to collectively create a lucrative pool of opportunities for the leading bunch of companies in the global marketplace. The market is also witnessing the development of novel and effective products for use in trauma care, which stands to be another important opportunity.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-2840

More from FMI‘s Healthcare, Pharmaceuticals & Medical Devices:

Bone Growth Stimulators Market Segmentation By Product – Invasive Bone Growth Stimulators, Non-Invasive Bone Growth Stimulators and Ultrasound Bone Growth Stimulators; By End User – Hospital, Ambulatory Surgical Centers, Orthopedic Clinics, and Home Care; By Application – Trauma Injury and Fractures, Spinal Fusion, and Osteogenesis; Others – Market Size, Growth, Forecast, Sales, Pricing Forecast, Share, Export Value, Export Volume, Trade: https://www.futuremarketinsights.com/reports/bone-growth-stimulators-market
Platelet Rich Plasma (PRP) Market Segmentation By Types – Pure Platelet-Rich Plasma, Leukocyte Rich Platelet Rich Plasma; By Origin – Autologus PRP, Allogenic PRP, Homologus PRP; By Applications – Orthopedic Surgery, Cosmetic Surgery, General Surgery, Neurosurgery: https://www.futuremarketinsights.com/reports/platelet-rich-plasma-market
Ambulatory Surgical Centres Market Segmentation centre type – Single Speciality Centres, Multispecialty Centres; modality type – Hospital-based Ambulatory Surgical Centre, Freestanding Ambulatory Surgical Centre; service type – Diagnostic Services, Surgical Services; speciality area – Gastroenterology, Ophthalmology, Orthopedics, Pain/Neurology, Urology, Dermatology, Others: https://www.futuremarketinsights.com/reports/ambulatory-surgical-centre-market-092017

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Browse More: Healthcare, Pharmaceuticals & Medical Devices Market

Contact Us
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44 (0) 20 7692 8790

Sales: sales@futuremarketinsights.com

Press Office: Press@futuremrketinsights.com

FMI Blog: http://www.fmiblog.com/

Website: http://www.futuremarketinsights.com

SOURCE Future Market Insights

EY Announces OrthoPediatrics as Entrepreneur of The Year® 2018 Award Finalist in the Midwest

Posted On May 7, 2018 By OrthoSpineNews In Extremities /

WARSAW, Ind., May 04, 2018 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (NASDAQ:KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, is pleased to announce that Ernst & Young (EY) has named President & CEO, Mark Throdahl, a finalist for the Entrepreneur of The Year® 2018 Award in the Midwest Region. The awards program recognizes entrepreneurs excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. OrthoPediatrics was selected as a finalist by a panel of independent judges. Award winners will be announced at a gala on June 13 at Navy Pier Grand Ballroom in Chicago.

“We are thrilled to receive this prestigious recognition,” said Mr. Throdahl. “It validates our belief that entrepreneurship is much more than having a new idea. It’s about continuously reassessing our strategy and implementing the operating, quality, and financial systems that drive performance. It’s about consistent growth that attracts blue chip investors. And, most importantly, it’s about building an entrepreneurial culture that engages everybody in the Company. Truly, every OrthoPediatrics associate deserves credit for this recognition.”

For more than 30 years, the Entrepreneur of the Year program has expanded to recognize business leaders in more than 145 cities and more than 60 countries throughout the world. Regional award winners are eligible for consideration for the Entrepreneur of The Year National competition. Award winners in several national categories, as well as the Entrepreneur of The Year National Overall Award winner, will be announced at the Entrepreneur of The Year National Awards gala in Palm Springs, California, on November 17, 2018. The awards are the culminating event of the Strategic Growth Forum®, the nation’s most prestigious gathering of high-growth, market-leading companies.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 24 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, scoliosis and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 37 countries outside the United States.

Investor Contacts
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
tbui@theruthgroup.com / epoalillo@theruthgroup.com

New research ranks the effectiveness of nonsurgical treatments for knee osteoarthritis

Posted On May 1, 2018 By OrthoSpineNews In Extremities /

ROSEMONT, Ill., May 1, 2018 /PRNewswire-USNewswire/ — An estimated 45 percent of people are at risk of developing knee osteoarthritis (OA) in their lifetime. According to a network meta-analysis research article published in the May 1, 2018 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), the nonsteroidal anti-inflammatory drug (NSAID) naproxen was ranked most effective in individual knee OA treatment for improving both pain and function, and is considered a relatively safe and low-cost treatment method.

Nonsurgical treatments for knee OA supported by previous research evidence include strength training, low-impact aerobic exercises, NSAIDs, and weight loss in individuals with a body mass index over 25. This new research analyzed data from multiple trials to determine the relative effectiveness of various nonsurgical treatments for knee OA. The treatments that were compared and ranked included acetaminophen; ibuprofen; intra-articular (IA) or joint injections of cortisone; platelet-rich plasma (PRP); hyaluronic acid (HA); several NSAIDs, such as naproxen, celecoxib, and diclofenac; and both oral and IA placebo.

“This is the first comprehensive mixed-comparison analysis comparing best-evidence scientific research and excluding lower quality studies that can bias the outcomes,” said lead author and orthopaedic surgeon David Jevsevar, MD, MBA. “Using a statistical ranking technique, we worked to provide evidence regarding which of the most common NSAIDs are most likely to decrease pain and improve function, and we attempted to fill in the gaps in evidence for more inconclusive treatments such as HA, PRP, and corticosteroids.”

Authors analyzed 53 randomized controlled trials that examined knee OA treatments for at least 28 days and included a minimum of 30 participants per study group. Knee OA treatments were ranked on a scale of one to five, with one being the most effective. They found the following:

For pain reduction, cortisone injections provided the greatest short-term (4 to 6 weeks) pain relief, followed by ibuprofen, PRP injections, naproxen, and celecoxib.
Naproxen ranked the highest for probability for improving function, followed by diclofenac, celecoxib, ibuprofen, and PRP injections.
Naproxen was ranked the most effective individual knee OA treatment for improving both pain and function followed by cortisone injections, PRP injections, ibuprofen and celecoxib.
HA injections did not achieve a rank in the top five treatments for pain, function, or combined pain and function. An analysis of 12 articles also found that results with HA are not significantly different from those with IA placebo for treatment of knee OA.

“Because knee OA has both a high disease burden and high treatment costs, additional prospective studies using similar outcomes, timelines, and measures of clinically important changes are needed,” explained Dr. Jevsevar. “While the information in this analysis is helpful to physicians, patients also can benefit from these findings and use it with their doctors to weigh all possible treatment options.”

Although the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.

More information about the AAOS and JAAOS
Follow the AAOS on Facebook, Twitter and Instagram
Follow the conversation about JAAOS on Twitter

Disclosures
From the Department of Orthopaedics, Dartmouth-Hitchcock Medical Center, Lebanon, NH (Dr. Jevsevar), American Academy of Orthopaedic Surgeons, Rosemont, IL (Mr. Shores, Mr. Mullen, Ms. Schulte, and Dr. Cummins), and Franciscan Orthopedic Associates, Tacoma, WA (Dr. Brown). J Am Acad Orthop Surg 2018; 26:325-336. DOI: 10.5435/JAAOS-D-17-00318

SOURCE American Academy of Orthopaedic Surgeons

Episurf Medical enters into distribution agreement in Hong Kong and establishes subsidiary in the US

Posted On April 27, 2018 By OrthoSpineNews In Extremities /

APR 26, 2018

Episurf Medical (NASDAQ: EPIS B) today announces that the company has entered into a distribution agreement in Hong Kong with Pacific Medical Systems. This is a first step in the company’s strategy of opening new markets in Asia. Pål Ryfors, CEO Episurf Medical, says that “we have received very encouraging feedback from leading surgeons in Hong Kong, confirming that Episealer® will help them to treat patients in the so-called treatment gap. We are happy to have appointed Pacific Medical Systems as our distributor, and Hong Kong will, as our first market in Asia where our technology is ready to be marketed, also be an important reference during our further expansion in the region.”

The company also communicates that it has established a subsidiary in the US, Episurf Medical Inc. This subsidiary is established for the purpose of conducting clinical studies for regulatory purposes in the US, as previously communicated.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

EOS imaging Announces New EOS® System Installations in Two U.S. Private Orthopedic Practices

Posted On April 25, 2018 By OrthoSpineNews In Extremities, Spine /

April 25, 2018

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – PME), the pioneer of 2D/3D imaging and data solutions for orthopedics, today announced that University Orthopedics in Providence, Rhode Island, and the Hey Clinic for Scoliosis and Spine Surgery in Raleigh, NC, have installed the EOS® system for low-dose, 2D and 3D imaging of patients. Both practices are part of the U.S. private practice sector, which amounts to 73 percent of all orthopedic practices in the country.

University Orthopedics is a multiple facility private practice in Rhode Island for patients with orthopedic related conditions and injuries. University Orthopedics directs many clinical research efforts intended to innovate new orthopedic surgery techniques, new surgical implant devices that improve the success of various procedures, and new ways to prevent orthopedic injury.

“We believe in using advanced technology to provide the safest and best healthcare possible” said Dr. Alan Daniels, Adult Spine Deformity Orthopedic Surgeon and Partner at University Orthopedics. “EOS® provides extremely high-quality full-body images for pediatric and adult patients at lower radiation doses than traditional x-rays, increasing patient safety. The EOS® images allow us to carefully assess the entire skeleton, so we can provide optimal individualized patient-specific care.”

Weber Shill, CEO of University Orthopedics, added: “I saw the clinical and educational benefits of the EOS® system immediately and was enthusiastic about getting behind a project that our surgeons were so motivated about and I knew our patients would appreciate. Like any healthcare organization today, we have to be cognizant about our capital expenditures, and EOS imaging custom finance program for the private sector facilitated our acquisition.”

For more than 13 years, the Hey Clinic has served patients with spinal conditions from North Carolina and beyond through a full array of treatment options. The clinic, recently relocated to a new facility on the Duke Raleigh Hospital campus, is committed to personalized attention, generous appointment times and a strong emphasis on patient education and engagement.

“When we decided to update our imaging options, we thoroughly researched available technologies and determined that the EOS® system would best serve our patients with its high image quality for diagnostics, low radiation to decrease cancer risk and 3D modeling capabilities for treatment planning,” commented Dr. Lloyd Hey, Orthopedic Surgeon and Founder of the Hey Clinic. “In addition, EOS® will help us facilitate educating patients and families about their condition and treatment choices. We are excited to work with EOS imaging to improve patient care.”

“We are encouraged to see a growing number of private practices adopting the EOS® system” said Marie Meynadier, Chief Executive Officer of EOS imaging. “Our technology has received strong recognition from academic and non-academic hospitals, both clinically and in terms of operational value. Private practices play an important role in orthopedic care, and we will do our best to support them in providing our low dose, 2D/3D solutions to a growing number of patients.”

About EOS imaging
EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopaedics combining equipment and services and targeting a $2B per year market opportunity. EOS imaging is currently present in 31 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 250 installed EOS® platforms representing around one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017.

For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA – PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Contacts

EOS imaging
Marie Meynadier
CEO
Ph: +33 (0)1 55 25 60 60
investors@eos-imaging.com
or
Press Relations (US)
Joanna Zimmerman
The Ruth Group
Ph: 646-536-7006
jzimmerman@theruthgroup.com
or
Investor Relations (US)
Matt Picciano / Emma Poalillo
The Ruth Group
Ph: 646-536-7008 / 7024
EOS-imagingIR@theruthgroup.com

Samumed’s Osteoarthritis and Tendinopathy Research Selected for Multiple Presentations at the 2018 Osteoarthritis Research Society Int’l World Congress

Posted On April 23, 2018 By OrthoSpineNews In Extremities /

SAN DIEGO, April 23, 2018 (GLOBE NEWSWIRE) — Samumed, LLC, a leader in Wnt research and development, today announced it will present its most recent clinical and preclinical data on the company’s investigational Wnt pathway inhibitors for the treatment of osteoarthritis (SM04690) and tendinopathy (SM04755) at the 2018 Osteoarthritis Research Society International World Congress, to be held April 26-29, 2018 in Liverpool, U.K.

“We are honored to present our work on the first potential disease modifying treatment in osteoarthritis and our first-in-class topical tendinopathy treatment at the OARSI congress. Our encouraging findings continue to drive our innovative research in Wnt pathway modulation for potential therapeutic options currently lacking in the clinical space,” said Dr. Yusuf Yazici, Samumed’s Chief Medical Officer.

Oral Presentation Details:


Abstract Title	Date/Time	Session Title

Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway – Oral Presentation #27	Friday, April 27 10:45-12:00pm BST	Plenary Session 4 – Non-Cartilaginous Soft Tissues in OA: Tendons, Ligaments and Synovium

Poster Presentation Details:


Abstract Title	Date/Time	Session Title

SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical Osteoarthritis Models – Poster #98	Friday, April 27 12:30-1:00pm and 4:30-5:00pm BST Saturday, April 28 4:15-5:00pm BST	OA: Cartilage & Bone


Radiographic Outcomes Were Concordant with Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) Strict Response: Post-Hoc Analysis from a Phase 2 Study of a Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment – Poster #466	Friday, April 27 12:30-1:00pm and 4:30-5:00pm BST Saturday, April 28 4:15-5:00pm BST	OA: Clinical Aspects & Outcomes


Joint Space Width Inclusion Criteria Can Reduce Knee Osteoarthritis Trial Heterogeneity: Post-Hoc Data from a Phase 2 Trial of Wnt Pathway Inhibitor, SM04690 – Poster #518	Friday, April 27 12:30-1:00pm and 4:30-5:00pm BST Saturday, April 28 4:15-5:00pm BST	Clinical Research Methods


Results from a 52-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis – Poster #550	Friday, April 27 12:30-1:00pm and 4:30-5:00pm BST Saturday, April 28 4:15-5:00pm BST	Therapy – Intraarticular

Further details can be found on the OARSI website at https://2018.oarsi.org/. A copy of the presentation materials can be accessed by visiting the Publications section of the Samumed website after the presentations conclude.

In addition, Samumed will be holding a scientific symposium at 12:15pm BST on Saturday, April 28 entitled, “Advancing Disease Modification in Knee Osteoarthritis: Clinical Implications of Wnt Pathway Inhibition.” This symposium will feature highly esteemed faculty: Dr. Timothy McAlindon, Dr. Rik Lories, Dr. Nancy E. Lane, and Dr. Yusuf Yazici.

About Osteoarthritis Research Society International
The Osteoarthritis Research Society International (OARSI) is the leading medical society for advancing the understanding, early detection, treatment and prevention of osteoarthritis (OA) through its exclusive dedication to research. OARSI’s passion and area of focus is on OA, a debilitating disease affecting more than 600 million people around the world. With more than 30 years of experience serving the OA community, OARSI provides the necessary framework, expert resources and support for its international constituents to address the challenges of OA so that the knowledge gained can ultimately be used to help improve patient care and patient outcomes.

About SM04690
SM04690 is a small molecule inhibitor of the Wnt pathway administered as an intra-articular injection, and is being developed as a potential disease modifying drug for osteoarthritis (DMOAD). Preclinical data suggested SM04690 has a dual mechanism of action with three specific effects on joint health – generating new articular cartilage, slowing down cartilage degradation, and reducing inflammation in the joint. Additional information on Samumed’s SM04690 osteoarthritis program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=20

About SM04755
SM04755 is a small-molecule Wnt pathway inhibitor and is being developed as a potential topical therapeutic for tendinopathy. Preclinical data on SM04755 have been previously shown to inhibit inflammation, reduce fibrosis, and increase tenocyte differentiation (tendon repair). Additional information on Samumed’s SM04755 tendinopathy program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=13

About Samumed
Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Samumed’s clinical pipeline can be found here: https://www.samumed.com/pipeline/default.aspx

Corporate Contact:
Erich Horsley
Samumed, LLC
erich@samumed.com
858-365-0200

Investor Contact:
Ashley Robinson
LifeSci Advisors
arr@lifesciadvisors.com
617-535-7742

Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt@lifescipublicrelations.com
646-627-8384

Misonix to Present at the 43rd Annual Deutsche Bank Health Care Conference on May 8

Posted On April 23, 2018 By OrthoSpineNews In Extremities /

FARMINGDALE, N.Y., April 23, 2018 — Misonix, Inc. (NASDAQ:MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the Deutsche Bank 43^rd Annual Health Care Conference held at the Intercontinental Hotel in Boston, Massachusetts on Tuesday, May 8, 2018. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, will be making a company presentation at 1:30 p.m. ET that day followed by a question and answer session.

Mr. Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be available to meet with institutional investors in one-on-one meetings throughout the day.

The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com. If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at mson@jcir.com.

About Misonix, Inc.
Misonix, Inc. (NASDAQ:MSON) designs, develops, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration. Misonix is focused on leveraging its proprietary ultrasonic technology to become the standard of care in operating rooms and clinics around the world. Misonix’s proprietary ultrasonic medical devices are used in a growing number of medical procedures, including spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. At Misonix, Better Matters to us. That is why throughout the Company’s 59-year history, Misonix has maintained its commitment to medical technology innovation and the development of ultrasonic surgical products that radically improve patient outcomes. Additional information is available on the Company’s web site at www.misonix.com.

Contact:
Joe Dwyer									Joseph Jaffoni, Norberto Aja, Jennifer Neuman
Chief Financial Officer									JCIR
Misonix, Inc.									212-835-8500 or mson@jcir.com
631-927-9113

First Case for Augmented Shoulder Baseplate

Posted On April 18, 2018 By OrthoSpineNews In Extremities /

By: Elizabeth Hofheinz, M.P.H., M.Ed., April 17, 2018

Zimmer Biomet Holdings, Inc., based in Warsaw, Indiana, has announced that the first surgical case utilizing its Comprehensive Augmented Baseplate was performed by John W. Sperling, M.D., an orthopedic surgeon at Mayo Clinic.

According to the company, “This newly cleared baseplate boasts a simplified circular design at three augment heights (3mm, 5mm and 7mm buildup), allowing for augment placement in any orientation to accommodate various unique bone anatomies. Its circular design also allows bone ingrowth into the rim of the baseplate for optimal fixation.”

“The Comprehensive Augmented Baseplate is a component of the Comprehensive Reverse Shoulder System, a next-generation reverse shoulder prosthesis engineered to offer high-quality intraoperative flexibility and clinically proven technologies.”

“The system aims to minimize the potential challenges of removing well-fixed humeral stems by allowing conversion to a reverse shoulder using any of the existing Comprehensive stems. Additionally, the Comprehensive Augmented Baseplate leverages Mayo Clinic’s patented methodology for the optimization of shoulder arthroplasty components developed by Dr. Sperling at Mayo Clinic, Rochester, Minn., to provide relevant sizing for a conservative approach to bone removal to preserve bone stock if a future revision procedure is necessary.”

READ THE REST HERE

Conventus Orthopaedics Appoints Jonathan Isenburg as Chief Financial Officer

Posted On April 13, 2018 By OrthoSpineNews In Extremities /

MINNEAPOLIS, April 12, 2018 /PRNewswire/ — Conventus Orthopaedics, a medical device company revolutionizing fracture repair surgery, today announced the appointment of Jonathan Isenburg as its new Chief Financial Officer. Mr. Isenburg brings corporate finance and executive experience to Conventus spanning both entrepreneurial and public company settings. Since April 2015, Mr. Isenburg served as CFO at Infraredx, Inc., where he led the cardiovascular imaging start-up through a dual-track IPO and M&A process that culminated in a sale to a publically traded strategic buyer.

“I am pleased to welcome Jonathan to the Conventus team. We will benefit from his expertise and leadership as we continue to grow commercial operations and accelerate development to bring the CAGE platform technology to additional types of fractures,” said Matthew Jewett, Chief Executive Officer of Conventus. “Jonathan is an experienced medical device industry executive who has excelled in corporate finance, strategy, business development and operations. He has a proven track record of success and we look forward to utilizing his many talents.”

Mr. Isenburg said, “It is with much enthusiasm that I join the outstanding Conventus team who has developed true game-changing technology for the treatment of simple and complex fractures throughout the anatomy. I look forward to working with them to grow the business and bring this innovative and less invasive surgical solution to more patients.”

Prior to his most recent role as CFO of Infraredx, Inc., Mr. Isenburg served as a Manager in Financial Advisory Services at RSM from 2008 to 2013. Mr. Isenburg was a CPA who began his career as an auditor at PricewaterhouseCoopers. He earned his Bachelor’s degree in Accounting from UMASS—Amherst and a graduate degree in Finance from Boston University.

About Conventus Orthopaedics, Inc.

Conventus Orthopaedics, Inc. was founded by a team of medical device professionals and physicians with the sole purpose of improving patient care by creating a 3-dimensional platform technology with less invasive solutions to a broad range of challenging periarticular fractures. Taking its name from the Latin word for coming together or union, Conventus Orthopaedics is focused on creating less invasive solutions to fractures in and around the joints. The company is dedicated to working with surgeons to improve healing and enable their patients’ return to normal activities.

SOURCE Conventus Orthopaedics, Inc.

OrthoSpineNews Interview with Mark Foster, President and Chief Commercialization Officer at Trice Medical

Posted On April 10, 2018 By OrthoSpineNews In Extremities, Top Stories /

Good afternoon Mark, thank you so much for talking with us today. We really appreciate you taking the time. Would you mind giving us a brief introduction and sharing a bit about your background?

Sure thing. I am the President and Chief Commercialization Officer here at Trice. I have been here for a little under two years and before that was at Smith & Nephew for 8 years. My last role at Smith & Nephew was Vice President of U.S. for their Sports Division. Before that I was at Boston Scientific for 8 years, and I graduated from the University of Richmond.

Mark, we’ve seen a lot of buzz around the mi-Eye 2 lately. What originally prompted the creation of this innovative technology?

As you may know, there have been some other technologies that took a swing, if you will, at in office arthroscopy. Unfortunately, they may have been a little ahead of their time. They basically tried to miniaturize a traditional arthroscopy tower, which still leaves you with a high capital cost, reusable components and multiple steps to set up; all of which make it hard to adopt in a busy office setting. So, the mi-eye was founded by asking the question- “Can we take a needle and put optics on it?” We started with a totally different view of the market compared to what had already been tried. Essentially, we took a 14-gauge needle and put optics through it, allowing us to deliver a high-quality image in a fully disposable product, that can be used readily and quickly in an office setting.

The mi-eye 2 is actually our 3^rd generation camera that has hit the market. As you know, the chips have gotten better and better, as well as more cost effective. We have come to a point where you can finally get an operating room type image, in a disposable needle, at a cost-effective price. This image gives patients instant answers because it is used by the physician in the office.What do you see as the biggest value of the mi-eye 2 to the various stakeholders involved?

Well, it is the first product I’ve been around that can bring major value to the three main stakeholders involved in the healthcare environment.

Patients: Consider yourself a patient with a torn meniscus or labrum, most physicians know from your physical exam that you’ve got some pathology. Yet in today’s world, you still have to go get that MRI. So, you have to take another day off of work, add an additional office visit, and so on which gets expensive and time consuming. Because the mi-eye was designed to be used in the clinical setting, it saves the patient a tremendous amount of time and money. Or, imagine you are the patient that has had a negative MRI and still has lingering knee pain. I have been in those cases and seen the relief on a patient’s face when the surgeon shows them cartlidge damage on the tablet and let’s them know that they “weren’t crazy.” They can then confidently move forward with treatment.

Physicians: Our surgeons use the mi-eye 2 not only because of the value to the system. They love the fact that they can get a dynamic view inside of the joint by using the camera in the office. The MRI’s are a wonderful tool, but they are a static image of the body at one point in time. The mi- eye allows the physicians to literally have their eye inside of the patient to achieve dynamic diagnostics. Additionally, they can confidently deliver biologics under direct visualization through the lumen of the needle.

Providers: Often times, something that is great for patients might be very expensive. Or if it’s great for the system, maybe it doesn’t fit a clinical need of the physician. In this case, we have peer-reviewed data supporting the fact that for intra-articular pathology, the mi-eye performed on the initial patient visit is the most cost-effective way to manage their imaging needs.

To that point, how does the mi-eye compare with the other options that are on the market?

Well we don’t really have true, comparable competitors in the market at this time. Our real cost competitor is the MRI. Looking at our device in a single day setting, compared to the amount of time, office visits, MRI costs, and MRI reads, we are really in a great spot. As I mentioned earlier, the mi-eye provides incredible value to all parties involved. However, the MRI and Ultrasound will never and should never go away. They are wonderful tools and will always have a place. The mi-eye is just another great diagnostic option for today’s busy surgeon.

What are some of the other things you are excited about as you look at what’s ahead for Trice?

We are really excited about getting the CE mark two weeks ago and getting Health Canada approval. In many countries around the world, it can take weeks or months to get MRI’s so we really have a great value proposition outside of the U.S.

We are also excited about the expansion of indications. We’ve seen recon physicians using mi-eye to determine partial vs total knee candidates. We’ve seen trauma physicians using it to confirm fracture reduction. And most recently, we launched our hip camera and the ability to get additional information inside of the hip while delivering an injection, or potentially removing the need for fluoro, is really quite powerful.

Well Mark we really appreciate you spending some time with us and giving us some keen insights into the mi-eye 2. Congratulations on all of the success and we are looking forward to what lies ahead!

Thanks guys, hope you have a great rest of your day.

More Information:

Trice Medical

Extremities